On April 27, 2026, the SURFSeq 5000 Dx Sequencing System officially secured National Medical Products Administration (NMPA) Class III Medical Device Registration Certificate. Becoming GeneMind's third clinically approved NGS platform after GenoLab M Dx and FASTASeq 300 Dx, this also marks a new milestone in GeneMind's clinical genetic sequencer layout, achieving dual DNA & RNA sequencing and full coverage of clinical applications.
Highlights of SURFSeq 5000 Dx：
Max 2.2 Tb per run, flexible for low-to-high throughput scenarios including targeted sequencing, WGS, and cohort studies.
At this point, GeneMind has established a complete clinical sequencing matrix of FASTASeq 300 Dx (medium-low throughput), GenoLab M Dx (medium-high throughput), and SURFSeq 5000 Dx (high throughput), covering all scenarios from Gb to Tb levels and from DNA to RNA for regulatory-compliant sequencing requirements.
